TW200501936A - Fatigue improving agent - Google Patents

Fatigue improving agent

Info

Publication number
TW200501936A
TW200501936A TW093101022A TW93101022A TW200501936A TW 200501936 A TW200501936 A TW 200501936A TW 093101022 A TW093101022 A TW 093101022A TW 93101022 A TW93101022 A TW 93101022A TW 200501936 A TW200501936 A TW 200501936A
Authority
TW
Taiwan
Prior art keywords
fatigue
composition
improving agent
effect
fatigue improving
Prior art date
Application number
TW093101022A
Other languages
English (en)
Other versions
TWI322008B (en
Inventor
Kenji Fujii
Kazunori Hosoe
Taizo Kawabe
Takayoshi Hidaka
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of TW200501936A publication Critical patent/TW200501936A/zh
Application granted granted Critical
Publication of TWI322008B publication Critical patent/TWI322008B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TW093101022A 2003-01-31 2004-01-15 Fatigue improving agent including reduced coenzyme q10 TWI322008B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003024758 2003-01-31

Publications (2)

Publication Number Publication Date
TW200501936A true TW200501936A (en) 2005-01-16
TWI322008B TWI322008B (en) 2010-03-21

Family

ID=32820773

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093101022A TWI322008B (en) 2003-01-31 2004-01-15 Fatigue improving agent including reduced coenzyme q10

Country Status (11)

Country Link
US (1) US8946303B2 (zh)
EP (1) EP1588703B1 (zh)
JP (1) JP4644121B2 (zh)
KR (1) KR100696924B1 (zh)
CN (1) CN1723015A (zh)
AU (1) AU2004208588B2 (zh)
CA (1) CA2511080C (zh)
NO (1) NO20053051L (zh)
RU (1) RU2304432C2 (zh)
TW (1) TWI322008B (zh)
WO (1) WO2004066988A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065672A1 (en) * 2004-01-08 2005-07-21 Kaneka Corporation Antiaging composition
US7708990B2 (en) 2004-03-23 2010-05-04 Kaneka Corporation Coenzyme Q compositions persisting in blood
KR20060130759A (ko) * 2004-03-23 2006-12-19 가부시키가이샤 가네카 혈중 지속성 보효소 ｑ 조성물
TW200603786A (en) * 2004-05-11 2006-02-01 Kaneka Corp Anti-fatigue composition
US20080254016A1 (en) * 2005-03-29 2008-10-16 Kaneka Corporation Composition For Increasing Anti-Oxidation Activity In Blood
US20090226408A1 (en) * 2005-06-24 2009-09-10 Kaneka Corporation Anti-fatigue composition
JP5023253B2 (ja) * 2005-09-14 2012-09-12 株式会社ノエビア 疲労感、倦怠感の予防及び治療用組成物
JP5103374B2 (ja) * 2006-03-13 2012-12-19 株式会社カネカ 心機能不良改善剤または心機能維持剤
US10583098B2 (en) * 2006-05-02 2020-03-10 Sung Lan Hsia Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds
WO2008007728A1 (fr) * 2006-07-13 2008-01-17 Kaneka Corporation Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif
JP2008239528A (ja) * 2007-03-26 2008-10-09 Lion Corp 目及び脳機能改善剤
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
JP5283359B2 (ja) * 2007-08-30 2013-09-04 株式会社カネカ 還元型補酵素ｑ含有組成物
JP5558823B2 (ja) * 2007-10-05 2014-07-23 株式会社カネカ 還元型補酵素ｑ１０の製造方法
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
JPWO2009136587A1 (ja) * 2008-05-08 2011-09-08 株式会社カネカ 抗疲労組成物
NZ705666A (en) * 2009-01-23 2016-06-24 Wyeth Llc A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
US9040747B2 (en) 2009-10-16 2015-05-26 Kaneka Corporation Method for producing reduced coenzyme Q10, method for stabilizing same, and composition comprising same
US8865660B2 (en) 2010-12-10 2014-10-21 Broady Health Sciences, Llc Method of treating neurogenic overactive bladder in a mammal or method of treating non-psychological stress-related bladder dysfunction in a female mammal by administering at least on jasmonate
JP6024942B2 (ja) * 2012-02-29 2016-11-16 株式会社福山こめ酢 テストステロン分泌促進剤、抗疲労剤及びその製造方法と利用
CN103371317A (zh) * 2012-04-25 2013-10-30 山东邦奥创业生物科技有限公司 一种核糖功能食品
WO2014153285A1 (en) * 2013-03-16 2014-09-25 Sinatra Stephen T Equine supplement
RU2540476C1 (ru) * 2014-03-27 2015-02-10 Федеральное государственное унитарное предприятие "Государственный ордена Трудового Красного Знамени научно-исследовательский институт химии и технологии элементоорганических соединений" (ФГУП "ГНИИХТЭОС") Повышение работоспособности
JP2018527406A (ja) * 2015-08-11 2018-09-20 アカール ファーマ ピーティーワイ リミテッドＡｋａａｌ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ Ｓ１ｐ受容体モジュレーターを含む組成物
CN107007606B (zh) * 2016-02-04 2021-10-26 南京舒鹏生物科技有限公司 一种用于干燥综合症预防及治疗的药物及其组合
CN106177925A (zh) * 2016-08-25 2016-12-07 明光市昊昊蜂业有限公司 一种蜂王浆美容保健品
JP6252922B2 (ja) * 2016-09-27 2017-12-27 ビーエイチエヌ株式会社 テストステロン分泌促進剤、抗疲労剤及びその製造方法と利用
CN106617030A (zh) * 2016-12-12 2017-05-10 钦州学院 一种体力恢复剂及其制备方法
US11419830B2 (en) 2017-05-17 2022-08-23 Berg Llc Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof
CN110801018A (zh) * 2019-11-08 2020-02-18 广东医科大学 辅酶q10维生素c运动含片

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938204B2 (ja) 1976-02-14 1984-09-14 エーザイ株式会社 再生不良性貧血治療剤
JPS5942649B2 (ja) * 1976-02-14 1984-10-16 エーザイ株式会社 重症筋無力症治療剤
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
JPH07330584A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd 疲労改善剤
JPH07330593A (ja) * 1994-06-09 1995-12-19 Taisho Pharmaceut Co Ltd 疲労改善剤
JPH1053520A (ja) * 1996-06-03 1998-02-24 Takeda Chem Ind Ltd 抗疲労剤
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
AU739353B2 (en) * 1997-03-27 2001-10-11 Medifoods Inc. Nutritional composition for improvements in cell energetics
JPH10287560A (ja) * 1997-04-11 1998-10-27 Taisho Pharmaceut Co Ltd 医薬組成物
DE19806947A1 (de) * 1998-02-19 1999-08-26 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Chinon und oder mindestens einem Hydrochinon sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen
WO2000057871A2 (en) * 1999-03-30 2000-10-05 Purdue Research Foundation Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
WO2001032040A1 (en) 1999-11-01 2001-05-10 University Of Massachusetts Method for selective delivery of lipid-soluble antioxidants into the polar lipid fraction of a food product
EP1231886A4 (en) * 1999-11-24 2005-10-12 Access Business Group Int Llc COMPOSITION FOR THE SKIN SURFACE
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
CA2406570C (en) 2000-05-09 2011-07-12 Kaneka Corporation Dermal compositions containing coenzyme q as the active ingredient
ZA200109677B (en) * 2000-09-06 2002-06-25 Technikon Pretoria A nutritional and pharmaceutical composition.
JP2002363073A (ja) 2001-05-09 2002-12-18 Crescendo Corporation スポーツパフォーマンス
WO2002092067A1 (fr) * 2001-05-10 2002-11-21 Kaneka Corporation Composition pour administration transmucosale contenant une coenzyme q en tant qu'ingredient actif
JP2003119127A (ja) 2001-10-10 2003-04-23 Kanegafuchi Chem Ind Co Ltd 安定な還元型補酵素ｑ製剤
TWI329513B (en) * 2001-10-12 2010-09-01 Kaneka Corp Use of reduced coenzyme q for lessening oxidative stress

Also Published As

Publication number Publication date
CA2511080C (en) 2015-10-13
NO20053051D0 (no) 2005-06-21
NO20053051L (no) 2005-08-31
KR20050092128A (ko) 2005-09-20
AU2004208588B2 (en) 2009-05-07
US8946303B2 (en) 2015-02-03
RU2005122409A (ru) 2006-01-20
EP1588703B1 (en) 2016-04-20
RU2304432C2 (ru) 2007-08-20
WO2004066988A1 (ja) 2004-08-12
AU2004208588A1 (en) 2004-08-12
CA2511080A1 (en) 2004-08-12
JPWO2004066988A1 (ja) 2006-05-18
AU2004208588A2 (en) 2004-08-12
EP1588703A1 (en) 2005-10-26
US20060165672A1 (en) 2006-07-27
TWI322008B (en) 2010-03-21
JP4644121B2 (ja) 2011-03-02
CN1723015A (zh) 2006-01-18
KR100696924B1 (ko) 2007-03-20
EP1588703A4 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
TW200501936A (en) Fatigue improving agent
AR051704A1 (es) Composicion para el consumo humano que brinda mejoras en la concentracion de la agudeza mental
WO2010002571A8 (en) Halitosis treatment
IL165268A (en) Polyaminoacids functionalized by alpha tocopherol and uses thereof, in particular for therapeutic applications
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
WO2010076731A3 (en) Vitamin d promoting sunscreen
AP2006003688A0 (en) 1,3-dioxane derivatives and analogues thereof useful in the treatment of I.A obesity and diabetes
PT1283038E (pt) Composições normalizadoras do ritmo circadiano
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
SG158183A1 (en) Sesamin/episesamin compositions
IL174594A (en) MANIPULATED NKT CELLS MODULATING THE Th1/Th2 BALANCE, USES AND THERAPEUTIC COMPOSITIONS THEREOF IN THE TREATMENT OF IMMUNE-RELATED DISORDERS
WO2007019575A3 (en) Methods for treating b-cell malignancies using taci-ig fusion molecule
EP1405629A3 (en) Exothermic article and the use thereof in whitening teeth
TW200637604A (en) Cosmetic compositions containing sophora alopecuroides L. extracts
ECSP056227A (es) Composición blanqueadora de cloro reductora de olor de blanqueado
WO2007059955A3 (en) Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
WO2005049058A8 (fr) Radix salviae miltiorrhizae, extrait et composition destines au traitement des maladies de resistance a l'aspirine
WO2004010924A3 (en) Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
WO2003080568A3 (en) Probucol derivatives
WO2006127759A3 (en) Antioxidant supplement composition and method of use
IL182297A0 (en) The use of winter savory (satureja montana) or the extracts thereof for the preparation of medicaments for the treatment of the premature ejaculation
GB9827121D0 (en) Agent for lowering endothelin levels
WO2004105780A3 (en) Compositions comprising gastrin compounds and their use in diabetes
MXPA04000517A (es) Medicamentos profilacticos de ascitis para aves de corral.
AU2003230830A8 (en) Treatment of type 1 diabetes before and after expression of predisposition markers

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees